Status:

RECRUITING

Menopur And Rekovelle Combination Study Version 2.0

Lead Sponsor:

Clinique Ovo

Collaborating Sponsors:

Ferring Pharmaceuticals

Conditions:

IVF

Controlled Ovarian Simulation

Eligibility:

FEMALE

18-40 years

Phase:

PHASE2

Brief Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main quest...

Detailed Description

In vitro fertilization (IVF) is a multi-step process that includes controlled ovarian stimulation, oocyte retrieval, fertilization, and embryo transfer. Success in IVF largely depends on how the ovari...

Eligibility Criteria

Inclusion

  • Women aged 18 to 40 years inclusively at the time of consent form signature
  • Diagnosis of unexplained infertility, tubal infertility, endometriosis stage I/II or male factor infertility
  • Regular menstrual cycles of 24-35 days
  • Presence of both ovaries
  • Early follicular phase FSH serum concentration \<10 IU/L measured between Day 2 and Day 5 of menstrual cycle within the previous 24 months
  • First IVF/ICSI cycle
  • IVF antagonist protocol prescribed
  • Partner or donor ejaculated sperm (fresh or frozen) used for fertilization

Exclusion

  • Women undergoing oocyte donation
  • Endometriosis stage III/IV
  • High risk of OHSS (AMH ≥ 35 pmol/L)
  • Body Mass Index (BMI) \> 40 kg/m2 Protocol number: IIS-1056 MARCS 2.0 Study Version: 1.1 - Date : 14 APR 2025 Page 12 of 28
  • Gynaecological haemorrhages of unknown aetiology
  • History of recurrent miscarriages defined as ≥ 3 consecutive losses
  • Renal or hepatic impairment
  • Hypersensitivity to any active ingredient or excipients in follitropin delta and/or HP-hMG
  • Tumours of hypothalamus or pituitary gland
  • Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome
  • Current or history of ovarian, uterine or mammary carcinoma
  • History of thrombophilia
  • Use of hormonal preparations (except for 17β-estradiol, testosterone gel, DHEA and thyroid medication) during the last menstrual cycle
  • Women participating in any other interventional research project

Key Trial Info

Start Date :

July 4 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2027

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06997900

Start Date

July 4 2025

End Date

August 1 2027

Last Update

July 31 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Ottawa fertility centre

Ottawa, Ontario, Canada

2

Clinique ovo

Montreal, Quebec, Canada, H4P 2S4